Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
dolutegravir/abacavir/lamivudine (572-Trii) (S-349572/S-265744/S-247303)
print preview
bookmark
share with colleague
General Information
Company
ViiV Healthcare Ltd.
Description
Single tablet formulation of integrase inhibitor and NRTI
Molecular Target
HIV integrase
Mechanism of Action
HIV integrase inhibitor; HIV reverse transcriptase inhibitor
Latest Stage of Development
Phase III
Indication
HIV / AIDS
Partner
Shionogi & Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information